Evidence mapPaperPMID 36432007Full record

ReviewMolecules (Basel, Switzerland)2022

Methylglyoxal in the Brain: From Glycolytic Metabolite to Signalling Molecule.

Zeyong Yang, Wangping Zhang, Han Lu, Shu Cai

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Role of cystathionine-β-synthase and hydrogen sulfide in down syndrome.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  10. Article
  11. Sirtuins, redox, and metabolic pathways in the brain of female PCOS mice.Journal of assisted reproduction and genetics · 2025
    Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. African walnut (Frontiers in nutrition · 2024
    Article
  18. 3D human stem-cell-derived neuronal spheroids forCurrent research in toxicology · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Zeyong YangDepartment of Anesthesiology, International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Embryo Original Disease, Shanghai Municipal Key Clinical Specialty, Huashan Rd. 1961, Shanghai 200030, China.ORCID 0000-0003-1331-0836
Wangping ZhangDepartment of Anesthesiology, Women and Children's Hospital of Jiaxing University, No. 2468 Zhonghuan East Road, Jiaxing 314000, China.
Han LuDepartment of Anesthesiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.ORCID 0000-0002-1753-0732
Shu CaiSchool of Nursing, Guangdong Pharmaceutical University, No. 283 Jianghai Avenue, Haizhu District, Guangzhou 510310, China.
Shanghai Jiao Tong University · CNGuangdong Pharmaceutical University · CNJiaxing University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in molecular biology technology have piqued tremendous interest in glycometabolism and bioenergetics in homeostasis and neural development linked to ageing and age-related diseases. Methylglyoxal (MGO) is a by-product of glycolysis, and it can covalently modify proteins, nucleic acids, and lipids, leading to cell growth inhibition and, eventually, cell death. MGO can alter intracellular calcium homeostasis, which is a major cell-permeant precursor to advanced glycation end-products (AGEs). As side-products or signalling molecules, MGO is involved in several pathologies, including neurodevelopmental disorders, ageing, and neurodegenerative diseases. In this review, we demonstrate that MGO (the metabolic side-product of glycolysis), the GLO system, and their analogous relationship with behavioural phenotypes, epigenetics, ageing, pain, and CNS degeneration. Furthermore, we summarise several therapeutic approaches that target MGO and the glyoxalase (GLO) system in neurodegenerative diseases.

Indexed as

Lactoylglutathione LyasePyruvaldehydeBrainGlycolysisMagnesium OxideLactoylglutathione LyaseMagnesium OxidePyruvaldehydebehavioural phenotypesbioenergeticsglyoxalasehomeostasismethylglyoxalneurodegenerativeside-product

Identifiers

PMID36432007
PMCPMC9696358
OpenAlexW4309312883

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.